Stock Ratings / Health Care / HSCS / forecast

LFWD (32) CUPR (21) CLGN (41) RGNT (31) ⌘ Pro Terminal →

HeartSciences Inc. (HSCS) 12-Month Stock Forecast & Price Target Cone

$3.31 -8.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.25

HeartSciences Inc. (HSCS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $16.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSCS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.31 (-8.31% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HSCS ranks #519 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HSCS compare to LFWD and CUPR in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, HSCS leads on earnings multiple (N/A) while HSCS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSCS?

▼

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.25 (-1.69%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HSCS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY HSCS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (29% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 47.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.09+1.3% Next Q

Q2 (-2Q)

Grade E$3.13+4.8% Next Q

Q3 (-1Q)

Grade E$3.28+0.9% Next Q

Current

Grade D-$3.31-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HSCS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HSCS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.48) forces dealer call-delta covering toward $5.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSCS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HSCS Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your HSCS Position Size: $10,000

Shares at $3.31: 3021.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.35

$7,100

$-2,900 (-29.0%)

12M Consensus BaseTarget $3.01

$9,094

$-906 (-9.1%)

12M Bull Case BreakoutTarget $5.51

$16,647

+$6,647 (+66.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$5	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSCS)

✓Walkthrough of HSCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HSCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.25%▲ ASCENDING CHANNEL

2026-11-03O $3.61H $3.61L $3.31C $3.31VOL 54.5K

RES: $6.00SUP: $2.21SMA50: $3.63SMA200: $2.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HSCS Butterfly Map → + Track HSCS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HSCS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HSCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HSCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSCS)

Health Care Rank #519 of 1016 ⚔️ LFWD vs HSCS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HSCS vs. LFWD, CUPR, CLGN, RGNT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HeartSciences Inc. (HSCS) ranks #519 by composite RQD confidence (38/100, grade D-) and #849 by equity capitalization ($16.0M). Within this direct 5-issuer industry benchmark cohort, HSCS leads on earnings valuation at N/A trailing P/E, while HSCS leads on capital efficiency and profitability with -35.0% ROIC and 59.1% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with HSCS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HSCS ACTIVE HeartSciences Inc.	D-	38/100	—	59.1%	-35.0%	-8.31%	$16.0M	Benchmark Subject
LFWD Lifeward Ltd.	E	32/100	—	96.0%	-35.0%	+0.71%	$16.9M	/lfwd-vs-hscs →
CUPR Cuprina Holdings (Cayman) Limited (Class A)	E	21/100	—	-1.3%	-35.0%	-3.80%	$13.5M	/cupr-vs-hscs →
CLGN CollPlant Biotechnologies Ltd	D-	41/100	—	64.8%	-35.0%	-6.02%	$11.9M	/clgn-vs-hscs →
RGNT Regentis Biomaterials Ltd.	E	31/100	—	—	-35.0%	+0.74%	$9.6M	/rgnt-vs-hscs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001468492

In its most recent audited fiscal period (FY2025, filed 2026-04-30), HeartSciences Inc. (HSCS) reported GAAP revenue of $4.3K (-0.7% vs. FY2024 revenue of $4.3K , and -76.8% cumulative change since FY2023) , GAAP net income of -$9.1M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (-0.2% YoY). On the balance sheet, HSCS closed FY2025 with $4.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$4.3K	-$9.1M	-$7.4M	-$7.4M	$4.2M	—
FY2024 (FY)	2025-04-30	$4.3K	-$8.8M	-$7.4M	-$7.4M	$5.7M	—
FY2023 (FY)	2024-04-30	$18.6K	-$6.6M	-$6.1M	-$6.1M	—	—

3. HSCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HSCS compare to LFWD and CUPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HSCS?

Where is HSCS trading relative to its 50-day, 200-day, and 52-week technical levels?

HSCS last traded at $3.31 (-8.31% on volume of 54,497 shares), positioning the stock -8.82% below its 50-day simple moving average ($3.63) and +21.69% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.63 to $5.25, HSCS sits at the 46.4% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

HSCS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HSCS's 12-month stock price target?

HeartSciences Inc. (HSCS) carries a 12-month consensus base price target of $3.01 (-9.1% from $3.31), with a bull-case target of $5.51 and a bear-case floor of $2.35.

Is HSCS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates HSCS D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: HSCS RQD Cockpit HSCS 12M Forecast HSCS Earnings & Move HSCS Dividends & DRIP HSCS Insiders & 13F HSCS Whale Options HSCS Profit Sankey HSCS News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HSCS — HeartSciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HSCS scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, which the rating scores at 3 of 20. The cash engine pillar reflects negative return on invested capital and zero free cash flow yield, meaning the business is not currently generating returns on the capital it consumes. For a prospective investor, the rating's implications are that upside depends on a turnaround in operating economics that the source data does not show, while the balance sheet and insider signals offer limited support. The sub-50 score places the name in a high-risk category by this framework; this is an analytical read of the rating, not personalized advice.

Business

HeartSciences Inc. is a NASDAQ-listed company classified under the Health Care sector and the Industrial Specialties industry, per the company profile. The source data does not describe its products, customers, or revenue model beyond these classifications. Reported revenue is $0.0M across the periods provided, with gross margin listed at 59.1%. Source data does not establish how the company generates or intends to generate revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-8.4M	$-9.1M	N/A	$-7.4M	$1.1M	N/A
FY 2024	$0.0M	$-8.4M	$-8.8M	N/A	$-7.4M	$2.6M	N/A
FY 2023	$0.0M	$-6.3M	$-6.6M	N/A	$-6.1M	N/A	N/A

Per the SEC financials, operating margin and net margin are each listed at -60%, and ROIC at -35%. Reported losses widened from FY 2023 to FY 2025 and cash declined from $2.6M to $1.1M over FY 2024–FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Source data does not provide debt amounts, so the Debt/Equity figure cannot be independently traced.

Recent Catalysts & News Wire Analysis

Proposed business combination: Multiple headlines reference a proposed business combination between HeartSciences and Fortitude Mining, including a definitive proxy statement filing. One headline describes the counterparty as an AI heart-test company combining with a cryptocurrency miner. Kalkine references a proposed NASDAQ:TUDE listing pursued through HSCS, tied to a data center addition in Nebraska.
Institutional positioning: A Stock Titan report states two investment chiefs may each hold over 5% of HSCS through the same two firms.
Market action: A Yahoo Finance report covers HSCS stock performance relative to medical peers. Per the market data, the price moved 7.12% on the reporting day with volume of 75,959.
Risk watch items: The business combination is the dominant catalyst; source data does not disclose its terms, valuation, or completion timeline.
Proprietary signals: None listed in the Butterfly Supply-Chain Graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be mapped from the source data. Sector correlation beyond the stated beta of 1.0 is not available in source data. The principal second-order exposure a prospective investor should monitor is the pending business combination, since headlines link HSCS to a counterparty in a different sector, and the outcome of that transaction could reshape the company's identity and capital structure.

Open Questions

What products or services generate the company's revenue, given reported revenue of $0.0M?
What are the terms, valuation, and expected closing timeline of the proposed business combination with Fortitude Mining?
What is the company's total debt, given that debt is listed as N/A in every reported period?
Why are EPS, P/E, and EV/EBITDA unavailable, and what share count underlies the $17.5M market cap?
What cash runway exists at the FY 2025 burn rate of roughly $7.4M in annual free cash flow outflow against $1.1M in cash?

HSCS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for HeartSciences Inc. (HSCS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HSCS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE markets.businessinsider.com • 21h ago

HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining

markets.businessinsider.com report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An AI heart-test company could combine with a cryptocurrency miner

Stock Titan report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

TradingView report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

Fortitude (Proposed NASDAQ:TUDE) Adds Aurora, Nebraska Data Center to Southwest Power Pool Markets via Demand Response, Pursuing Listing Through HeartSciences (NASDAQ:HSCS)

Kalkine report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two investment chiefs may each hold over 5% of HeartSciences (HSCS) through the same two firms.

Stock Titan report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Thermo Fisher to Report Q3 Earnings: What's in the Cards?

TradingView report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Fortitude Mining’s 15 MW Aurora Facility Now Active in Southwest Power Pool Markets Amid HeartSciences Merger Filing

Kalkine Media report covering HeartSciences Inc. (HSCS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSCS Bull vs. Bear Conversation Board — What's Your Call at $3.31?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSCS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.18 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HSCS (D- • RQD 39/100) a Buy at $3.61?

Welcome to the HSCS (HeartSciences Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.03 (-16.1%)

Spot @ $3.61

Pump the brakes on HSCS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HSCS, but look at what you are paying: current EV/EBITDA multiples with 59.1% gross margins. Unless HeartSciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.30 (+19.1%)

Spot @ $3.61

HSCS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HSCS, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $3.61 (52-wk range $1.63 - $5.25), any beat on forward guidance forces shorts and underweight funds to chase.